Journal of Immunology Research and Innovation

ABSTRACT

Understanding immunogenic cell death (ICD) and its ability to trigger potent antitumor immune responses has revolutionized cancer treatment. Innovative approaches like oncolytic virotherapy, photodynamic therapy (PDT), and nanotechnology have remarkable potential in promoting ICD and enhancing the immune response against cancer. Combining these therapies with immunotherapies improves effectiveness and reduces side effects. ICD can be induced by various agents such as chemotherapeutic drugs, oncolytic viruses, and PDT, activating endoplasmic reticulum stress and generating reactive oxygen species. Nanotechnology plays a crucial role in drug delivery and enhancing ICD induction. These advancements offer a transformative era in cancer treatment, leveraging the immune system's power and promising improved patient outcomes in the fight against cancer.

Article History

Received 22 July 2024; Revised 26 August 2024; Accepted 4 September 2024

KEYWORDS

1. Immunogenic cell death
2. Immunogenic cell death inducers
3. Danger-associated molecular patterns
4. Immunotherapy